Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 12/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905581 | 0.88 | PLA2G7 (0.52) | PLA2G7GPR84RAF1BRAFPIN1 | |
| SCHEMBL15280356 | 0.84 | PLA2G7 (0.37) | PLA2G7GPR84PIN1 | |
| SCHEMBL9904927 | 0.82 | PLA2G7 (0.52) | PLA2G7GPR84RAF1BRAFCDK8 | |
| SCHEMBL15262888 | 0.81 | PLA2G7 (0.58) | PLA2G7GPR84RAF1BRAF | |
| SCHEMBL15277235 | 0.80 | PLA2G7 (0.52) | PLA2G7GPR84RAF1BRAFCDK8 | |
| SCHEMBL15262340 | 0.79 | PLA2G7 (0.45) | PLA2G7GPR84 | |
| SCHEMBL9923530 | 0.78 | PLA2G7 (0.50) | PLA2G7GPR84RAF1BRAFCDK8 | |
| SCHEMBL9923513 | 0.78 | GPR84 (0.44) | PLA2G7GPR84BRAF | |
| SCHEMBL9904748 | 0.78 | PLA2G7 (0.42) | PLA2G7GPR84BRAF | |
| SCHEMBL9904954 | 0.77 | IDO1 (0.42) | PLA2G7GPR84RAF1BRAFPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | PLA2G7 6/4885GPR84 773/4885RAF1 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.